Renin-Angiotensin System Blockers and Statins Are Associated With Lower In-Hospital Mortality in Very Elderly Hypertensives

Journal of the American Medical Directors Association

Volumn 19, Issue 4, 2018, Pages 342-347

  Spannella, Francesco ^a,b   Giulietti, Federico ^a,b   Balietti, Paolo ^a,b   Cocci, Guido ^a,b   Landi, Laura ^a,b   Lombardi, Francesca Elena ^a,b   Borioni, Elisabetta ^a,b   Bernardi, Beatrice ^a,b   Rosettani, Giulia ^a,b   Bordoni, Valentina ^a,b   Sarzani, Riccardo ^a,b  

^a IRCCS INRCA U Sestilli Ancona   (Italy)

^b UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

Author keywords

cardiovascular drug; comorbidity; in hospital mortality; RAAS inhibition; statin; Very elderly

Indexed keywords

ALBUMIN; AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; ANGIOTENSIN RECEPTOR ANTAGONIST; C REACTIVE PROTEIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GLUCOSE; HEMOGLOBIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; POTASSIUM;

AGED; ALBUMIN BLOOD LEVEL; ARTICLE; FEMALE; GLUCOSE BLOOD LEVEL; HEMOGLOBIN BLOOD LEVEL; HOSPITAL ADMISSION; HOSPITAL MORTALITY; HOSPITALIZATION; HUMAN; HYPERTENSION; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; POTASSIUM BLOOD LEVEL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; VERY ELDERLY; CARDIOVASCULAR DISEASE; COMBINATION DRUG THERAPY; COMPARATIVE STUDY; FRAIL ELDERLY; ITALY; MORTALITY; PROGNOSIS; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; SURVIVAL RATE; TREATMENT OUTCOME;

AGED, 80 AND OVER; ANGIOTENSIN RECEPTOR ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CARDIOVASCULAR DISEASES; DRUG THERAPY, COMBINATION; FEMALE; FRAIL ELDERLY; HOSPITAL MORTALITY; HOSPITALIZATION; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERTENSION; ITALY; MALE; PROGNOSIS; PROSPECTIVE STUDIES; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 85034429815     PISSN: 15258610     EISSN: 15389375     Source Type: Journal    
DOI: 10.1016/j.jamda.2017.09.023     Document Type: Article

References (56)

1. Italy: WHO statistical profile. Country statistics and global health estimates by WHO and UN partners. Last updated: January 2015.
2. Fleg, J.L., Aronow, W.S., Frishman, W.H., Cardiovascular drug therapy in the elderly: Benefits and challenges. Nat Rev Cardiol 8 (2011), 13–28.
3. Cutler, J.A., Sorlie, P.D., Wolz, M., et al. Trends in hypertension prevalence, awareness, treatment, and control rates in United States adults between 1988-1994 and 1999-2004. Hypertension 52 (2008), 818–827.
4. Mancia, G., Fagard, R., Narkiewicz, K., et al. 2013 ESH/ESC guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 31 (2013), 1281–1357.
5. Beckett, N.S., Peters, R., Fletcher, A.E., et al. Treatment of hypertension in patients 80 years of age or older. N Engl J Med 358 (2008), 1887–1898.
6. Williamson, J.D., Supiano, M.A., Applegate, W.B., et al. Intensive vs standard blood pressure control and cardiovascular disease outcomes in adults aged ≥75 years: A randomized clinical trial. JAMA 315 (2016), 2673–2682.
7. Bursztyn, M., Hypertension, its treatment, frailty, falls, and mortality. Hypertension 70 (2017), 253–254.
8. Gruneir, A., Silver, M.J., Rochon, P.A., Emergency department use by older adults: A literature review on trends, appropriateness, and consequences of unmet health care needs. Med Care Res Rev 68 (2011), 131–155.
9. Levey, A.S., Stevens, L.A., Schmid, C.H., et al., CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration). A new equation to estimate glomerular filtration rate. Ann Intern Med 150 (2009), 604–612.
10. Januzzi, J.L., Richards, A.M., An international consensus statement regarding amino-terminal pro-B-type natriuretic peptide testing: The International NT-proBNP Consensus Panel. Am J Cardiol 101:3 suppl (2008), S1–S96.
11. Morris, J.N., Fries, B.E., Morris, S.A., Scaling ADLs within the MDS. J Gerontol A Biol Sci Med Sci 54 (1999), M546–M553.
12. Borson, S., Scanlan, J.M., Chen, P., Ganguli, M., The Mini-Cog as a screen for dementia: Validation in a population-based sample. J Am Geriatr Soc 51 (2003), 1451–1454.
13. Rozzini, R., Frisoni, G.B., Ferrucci, L., et al. Geriatric Index of Comorbidity: Validation and comparison with other measures of comorbidity. Age Ageing 31 (2002), 277–285.
14. Wooten, J.M., Pharmacotherapy considerations in elderly adults. South Med J 105 (2012), 437–445.
15. Brocco, S., Zamboni, M., Fantin, F., et al. Quality of care in congestive heart failure in the elderly: Epidemiological evidence of a gap between guidelines and clinical practice. Aging Clin Exp Res 22 (2010), 243–248.
16. Tinetti, M.E., McAvay, G., Trentalange, M., et al. Association between guideline recommended drugs and death in older adults with multiple chronic conditions: Population based cohort study. BMJ, 351, 2015, h4984.
17. Bo, M., Massaia, M., Raspo, S., et al. Predictive factors of in-hospital mortality in older patients admitted to a medical intensive care unit. J Am Geriatr Soc 51 (2003), 529–533.
18. Comba, M., Fonte, G., Isaia, G., et al. Cardiac and inflammatory biomarkers and in-hospital mortality in older medical patients. J Am Med Dir Assoc 15 (2014), 68–72.
19. Forasassi, C., Golmard, J.L., Pautas, E., et al. Inflammation and disability as risk factors for mortality in elderly acute care patients. Arch Gerontol Geriatr 48 (2009), 406–410.
20. Goodnough, L.T., Schrier, S.L., Evaluation and management of anemia in the elderly. Am J Hematol 89 (2014), 88–96.
21. Chao, C.T., Lin, Y.F., Tsai, H.B., et al., HINT Study Group. In nonagenarians, acute kidney injury predicts in-hospital mortality, while heart failure predicts hospital length of stay. PLoS One, 8, 2013, e77929.
22. Sarzani, R., Spannella, F., Giulietti, F., et al. NT-proBNP and its correlation with in-hospital mortality in the very elderly without an admission diagnosis of heart failure. PLoS One, 11, 2016, e0153759.
23. Bui, A.L., Grau-Sepulveda, M.V., Hernandez, A.F., et al. Admission heart rate and in-hospital outcomes in patients hospitalized for heart failure in sinus rhythm and in atrial fibrillation. Am Heart J 165 (2013), 567–574.
24. Bromfield, S.G., Ngameni, C.A., Colantonio, L.D., et al. Blood pressure, antihypertensive polypharmacy, frailty, and risk for serious fall injuries among older treated adults with hypertension. Hypertension 70 (2017), 259–266.
25. Stessman, J., Bursztyn, M., Gershinsky, Y., et al. Hypertension and its treatment at age 90 years: Is there an association with 5-year mortality?. J Am Med Dir Assoc 18 (2017), 277.e13–277.e19.
26. Benetos, A., Bulpitt, C.J., Petrovic, M., et al. An expert opinion from the European Society of Hypertension-European Union Geriatric Medicine Society Working Group on the management of hypertension in very old, frail subjects. Hypertension 67 (2016), 820–825.
27. Pajewski, N.M., Williamson, J.D., Applegate, W.B., et al., SPRINT Study Research Group. Characterizing frailty status in the Systolic Blood Pressure Intervention Trial. J Gerontol A Biol Sci Med Sci 71 (2016), 649–655.
28. Chow, C.K., Teo, K.K., Rangarajan, S., et al. Prevalence, awareness, treatment, and control of hypertension in rural and urban communities in high-, middle-, and low-income countries. JAMA 310 (2013), 959–968.
29. Ma, C., Cao, J., Lu, X.C., et al. Cardiovascular and cerebrovascular outcomes in elderly hypertensive patients treated with either ARB or ACEI. J Geriatr Cardiol 9 (2012), 252–257.
30. Van Vark, L.C., Bertrand, M., Akkerhuis, K.M., et al. Angiotensin-converting enzyme inhibitors reduce mortality in hypertension: A meta-analysis of randomized clinical trials of renin-angiotensin-aldosterone system inhibitors involving 158,998 patients. Eur Heart J 33 (2012), 2088–2097.
31. Bangalore, S., Fakheri, R., Toklu, B., et al. Angiotensin-converting enzyme inhibitors or angiotensin receptor blockers in patients without heart failure? Insights from 254,301 patients from randomized trials. Mayo Clin Proc 91 (2016), 51–60.
32. Strauss, M.H., Hall, A.S., The divergent cardiovascular effects of angiotensin converting enzyme inhibitors and angiotensin receptor blockers on myocardial infarction and death. Prog Cardiovasc Dis 58 (2016), 473–482.
33. Aronow, W.S., Fleg, J.L., Pepine, C.J., et al. ACCF/AHA 2011 expert consensus document on hypertension in the elderly: A report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. Circulation 123 (2011), 2434–2506.
34. Turgut, F., Balogun, R.A., Abdel-Rahman, E.M., Renin-angiotensin-aldosterone system blockade effects on the kidney in the elderly: Benefits and limitations. Clin J Am Soc Nephrol 5 (2010), 1330–1339.
35. Kereiakes, D.J., Neutel, J., Stoakes, K.A., et al. The effects of an olmesartan medoxomil-based treatment algorithm on 24-hour blood pressure levels in elderly patients aged 65 and older. J Clin Hypertens (Greenwich) 11 (2009), 411–421.
36. Mann, J.F., Schmieder, R.E., Dyal, L., et al. Effect of telmisartan on renal outcomes: A randomized trial. Ann Intern Med 151 (2009), 1–10 W1–2.
37. Viazzi, F., Leoncini, G., Pontremoli, R., Antihypertensive treatment and renal protection: The role of drugs inhibiting the renin-angiotensin-aldosterone system. High Blood Press Cardiovasc Prev 20 (2013), 273–282.
38. Sarzani, R., Spannella, F., Giulietti, F., et al. Cardiac natriuretic peptides, hypertension and cardiovascular risk. High Blood Press Cardiovasc Prev 24 (2017), 115–126.
39. Mancia, G., Giannattasio, C., Seravalle, G., et al. Protective effects of renin-angiotensin blockade beyond blood pressure control. J Hum Hypertens 23 (2009), 570–577.
40. Spannella, F., Giulietti, F., Balietti, P., et al. Plasma renin activity to plasma aldosterone concentration ratio correlates with night-time and pulse pressures in essential hypertensive patients treated with angiotensin-converting enzyme inhibitors/AT1 blockers. J Hypertens 35 (2017), 2315–2322.
41. Ponikowski, P., Voors, A.A., Anker, S.D., et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J 37 (2016), 2129–2200.
42. Shepherd, J., Blauw, G.J., Murphy, M.B., et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): A randomised controlled trial. Lancet 360 (2002), 1623–1630.
43. Glynn, R.J., Koenig, W., Nordestgaard, B.G., et al. Rosuvastatin for primary prevention in older persons with elevated C-reactive protein and low to average low-density lipoprotein cholesterol levels: Exploratory analysis of a randomized trial. Ann Intern Med 152 (2010), 488–496.
44. Pedro-Botet, J., Climent, E., Chillarón, J.J., et al. Statins for primary cardiovascular prevention in the elderly. J Geriatr Cardiol 12 (2015), 431–438.
45. Savarese, G., Gotto, A.M. Jr., Paolillo, S., et al. Benefits of statins in elderly subjects without established cardiovascular disease: A meta-analysis. J Am Coll Cardiol 62 (2013), 2090–2099.
46. Singh, N., Lee, J.Z., Huang, J.J., et al. Benefit of statin pretreatment in prevention of contrast-induced nephropathy in different adult patient population: Systematic review and meta-analysis. Open Heart, 1, 2014, e000127.
47. Bonetti, P.O., Lerman, L.O., Napoli, C., Lerman, A., Statin effects beyond lipid lowering—are they clinically relevant?. Eur Heart J 24 (2003), 225–248.
48. Foody, J.M., Shah, R., Galusha, D., et al. Statins and mortality among elderly patients hospitalized with heart failure. Circulation 113 (2006), 1086–1092.
49. Horwich, T.B., MacLellan, W.R., Fonarow, G.C., Statin therapy is associated with improved survival in ischemic and non-ischemic heart failure. J Am Coll Cardiol 43 (2004), 642–648.
50. Kruger, P., Fitzsimmons, K., Cook, D., et al. Statin therapy is associated with fewer deaths in patients with bacteraemia. Intensive Care Med 32 (2006), 75–79.
51. Wierzbicki, A.S., Poston, R., Ferro, A., The lipid and non-lipid effects of statins. Pharmacol Ther 99 (2003), 95–112.
52. Rosenson, R.S., Tangney, C.C., Casey, L.C., Inhibition of proinflammatory cytokine production by pravastatin. Lancet 353 (1999), 983–984.
53. Musial, J., Undas, A., Gajewski, P., et al. Anti-inflammatory effects of simvastatin in subjects with hypercholesterolemia. Int J Cardiol 77 (2001), 247–253.
54. Mortensen, E.M., Restrepo, M.I., Anzueto, A., Pugh, J., The effect of prior statin use on 30-day mortality for patients hospitalized with community-acquired pneumonia. Respir Res, 6, 2005, 82.
55. Liappis, A.P., Kan, V.L., Rochester, C.G., Simon, G.L., The effect of statins on mortality in patients with bacteremia. Clin Infect Dis 33 (2001), 1352–1357.
56. Yano, Y., Rakugi, H., Bakris, G.L., et al. On-treatment blood pressure and cardiovascular outcomes in older adults with isolated systolic hypertension. Hypertension 69 (2017), 220–227.